To evaluate the clinical efficacy and safety of the 3-month formulation of triptorelin (triptorelin pamoate) in the treatment of idiopathic central precocious puberty (ICPP) in children. A retrospective analysis was conducted of 49 children with ICPP treated with the 3-month formulation of triptorelin at Xiangya Hospital, Central South University, from May 2023 to September 2025. All patients received at least one injection and completed a 3-month follow-up. The numbers of patients who subsequently completed 6-, 9-, and 12-month follow-ups were 42, 26, and 11, respectively. Sex hormone levels, growth and development, and the differences between bone age and chronological age (ΔBA-CA) were assessed at 3, 6, 9, and 12 months after treatment initiation. At diagnosis, after the gonadotropin-releasing hormone agonist stimulation test, the peak luteinizing hormone (LH) level was (15.6±5.8) IU/L, the peak follicle-stimulating hormone (FSH) level was (8.5±3.9) IU/L, and the peak LH/FSH ratio was 1.9±0.9. After 3 months of treatment, 92% of the children achieved a peak LH <3 IU/L, all children had a peak LH/FSH ratio <0.6, and estradiol or testosterone decreased to prepubertal levels; this suppression was maintained through 12 months without rebound. In girls, uterine length was significantly reduced from baseline at 3, 6, 9, and 12 months (P<0.0125). In boys, testicular volume was significantly reduced from baseline at each follow-up (P<0.0125). At 3, 6, 9, and 12 months, ΔBA-CA was significantly decreased compared with baseline in all children (P<0.0125). The incidence of adverse reactions during treatment was low, no treatment discontinuations due to adverse events occurred, and overall tolerability was good. The 3-month formulation of triptorelin effectively suppresses the hypothalamic-pituitary-gonadal axis and delays bone age progression in children with ICPP, providing the potential to improve adult height, with a favorable safety profile. 目的: 评估曲普瑞林3月剂型（双羟萘酸曲普瑞林）在儿童特发性中枢性性早熟（idiopathic central precocious puberty, ICPP）治疗中的临床疗效与安全性。方法: 回顾性分析2023年5月—2025年9月中南大学湘雅医院诊治的49例接受曲普瑞林3月剂型治疗的ICPP患儿的临床资料。所有患儿均接受至少1次曲普瑞林3月剂型注射并完成3个月随访，后续完成6、9、12个月随访的例数分别为42例、26例和11例。分析治疗3、6、9、12个月后的性激素水平、生长发育情况及骨龄与实际年龄差值（differences between bone age and chronological age, ΔBA⁃CA）的变化。结果: 诊断时促性腺激素释放激素类似物激发试验后黄体生成素（luteinizing hormone, LH）峰值水平为（15.6±5.8）IU/L，卵泡刺激素（follicle⁃stimulating hormone, FSH）峰值水平为（8.5±3.9）IU/L，LH/FSH峰值比值为1.9±0.9。治疗3个月后，92%的患儿LH峰值<3 IU/L，所有患儿LH/FSH峰值比值<0.6，雌二醇或睾酮降至青春前期水平，且持续至12个月未见反弹。女性患儿治疗3、6、9、12个月后的子宫长度均较治疗前显著缩短（P<0.0125）;男性患儿的睾丸容积均较治疗前显著减少（P<0.0125）。治疗3、6、9、12个月后，所有患儿的ΔBA⁃CA与治疗前比较均显著减小（P<0.0125）。治疗期间不良反应发生率较低，患儿没有出现因不良事件导致的治疗中断，总体耐受性良好。结论: 曲普瑞林3月剂型治疗ICPP可有效抑制下丘脑-垂体-性腺轴，延缓骨龄进展，为改善成年身高提供可能，且安全性较高。.
使用 AI 将内容摘要翻译为中文，便于快速阅读
使用 AI 分析这篇文章的核心发现、关键要点和深度见解
由 DeepSeek AI 提供分析 · 首次使用需配置 API Key
PubMed · 2026-05-15
PubMed · 2026-04-15
PubMed · 2026-04-15
PubMed · 2026-05-15